Lung Cancer Study Group

Treatment of mutated CPNPC EGFR in the osimertinib era

The Doctor. António Calles was one of the speakers at the session “Hot Topics in CPNPC Therapeutics”, having presented the theme “Treatment of CPNPC mutated EGFR in the era of osimertinib”.

Cross-border perspectives are always an asset at events of the size and importance of the 10th GECP Congress/ 1st Portuguese Lung Cancer Congress and the contribution of Dr. António Calles was no exception. For the expert “early inhibition of treatment with osimertinib ensures a better response duration, better progression-free survival, more intracranial activity and, above all, longer survival”.

Get to know the expert’s statements by watching the video.

Posted in congressos, notícias, vídeo
©2022 Copyright GECP